Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy.
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response [ Read More ]
Listen to perspectives on CS diarrhea from Dr. David C. Metz, gastroenterologist and neuroendocrine tumor expert.
Dr. Valérie Vilgrain discusses SIRT Y-90 and the results of the SARAH trial.
April Christensen points out the value of clinical trials for patients as well as medical practices.
April Christensen points out the significance of finding the right practice manager organization and the resources they have to offer.
April Christensen speaks to how practice managers need to adjust to the ever-changing oncology market.
In an ever evolving health care environment, keeping up with reimbursement changes continues to be an ongoing challenge for practice managers.
April Christensen discusses why this benefit is so valuable during these meetings.